Cytiva is the global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020.
Fit for Purpose AAV Purification
Realizing the Perfect Scale for Cell and Gene Therapies.
Next steps in automated perfusion
Cytiva has introduced an innovation that supports the biotech industry’s move to continuous manufacturing.
Rapid, high-productivity purification of adeno-associated virus
Cytiva’s Fibro technology, known for its increased throughput and productivity in monoclonal antibody purification, is being extended to capture adeno-associated virus (AAV).
The gains of automated perfusion
Cytiva has introduced an innovation that supports the biotech industry’s move to continuous manufacturing. Called the Xcellerex Automated Perfusion System (APS), it simplifies processes and reduces risk when intensifying upstream operations.